Qiagen (NYSE:QGEN) Releases FY24 Earnings Guidance

Qiagen (NYSE:QGEN) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of at least $2.19 for the period, compared to the consensus estimate of $2.15. The company issued revenue guidance of at least $1.985 billion, compared to the consensus revenue estimate of $1.97 billion. Qiagen also updated its FY 2024 guidance to 2.190- EPS.

Analyst Upgrades and Downgrades

QGEN has been the subject of several recent analyst reports. Hsbc Global Res upgraded Qiagen to a “hold” rating in a report on Thursday, October 17th. HSBC lowered Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price objective for the company. in a report on Thursday, October 17th. Finally, Robert W. Baird increased their price target on Qiagen from $49.00 to $52.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.88.

Qiagen Stock Down 0.9 %

Shares of QGEN stock traded down $0.39 on Friday, hitting $43.76. 805,716 shares of the stock were exchanged, compared to its average volume of 1,170,116. The company has a current ratio of 1.77, a quick ratio of 1.46 and a debt-to-equity ratio of 0.27. The business has a 50-day moving average of $44.08 and a 200 day moving average of $43.70. The firm has a market capitalization of $9.99 billion, a P/E ratio of 112.74, a price-to-earnings-growth ratio of 3.35 and a beta of 0.41. Qiagen has a fifty-two week low of $37.51 and a fifty-two week high of $47.44.

Qiagen (NYSE:QGEN) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.54 by $0.03. The business had revenue of $501.87 million for the quarter, compared to the consensus estimate of $490.53 million. Qiagen had a net margin of 4.73% and a return on equity of 13.35%. Equities analysts anticipate that Qiagen will post 2.15 EPS for the current year.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.